Article
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Breast cancer research : BCR - 10 Dec 2018
Brooks Jennifer D, Comen Elizabeth A, Reiner Anne S, Orlow Irene, Leong Siok F, Liang Xiaolin, Mellemkjær Lene, Knight Julia A, Lynch Charles F, John Esther M, Bernstein Leslie, Woods Meghan, Doody David R, Malone Kathleen E, Bernstein Jonine L
Abstract excerpt
BACKGROUND: Tamoxifen treatment greatly reduces a woman's risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its active metabolites, and variants in this gene have been associated with reduced tamoxifen metabolism. The impact of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.